Aquaporin A/S Financial Performance Overview for Q3 2025
Company announcement No. 19/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Aquaporin A/S (ticker: AQP), an innovative water technology company focused on revolutionizing water filtration through biotechnology, has released its trading results for the third quarter of 2025, covering the period from January 1 to September 30, 2025.
Ulrik Lund Jakobsen, Chief Executive Officer of Aquaporin, remarked, "As anticipated, our commercial traction has grown within Q3 2025. The strong backlog suggests a clear path toward achieving our revenue expectations. We're diligently working on a strategic review to ensure our financial footing from 2026 onward, allowing us to maximize the potential of our extraordinary Aquaporin Inside® technology."
Key Financial Highlights
The figures for the period from January 1 to September 30, 2025, demonstrate important developments in Aquaporin's financial landscape:
- Revenues reached DKK 13.2 million, compared to DKK 32.8 million for the same period in 2024. Gains primarily stemmed from Forward Osmosis Market Development and Industrial Reverse Osmosis sales.
- Q3 2025 revenue stood at DKK 4.1 million, up from DKK 3.6 million in Q3 2024, indicating a 14% increase.
- EBITDA (before special items) resulted in a loss of DKK 14.5 million for Q3 2025, a slight improvement from the loss of DKK 16.0 million reported in Q3 2024, aligning with management's expectations.
- As of September 30, 2025, cash and cash equivalents amounted to DKK 8.8 million, a significant reduction from DKK 93.1 million recorded at the same time in 2024.
- The revenue guidance for 2025 has been revised to a range of DKK 40-50 million (previously DKK 60-80 million), while EBITDA guidance remains unchanged, expecting a loss within DKK (45) to (55) million, consistent with the guidance shared in mid-August.
Business Developments Highlight
Aquaporin has celebrated several notable business achievements this quarter:
- In August, successful trial outcomes in collaboration with Singapore's National Water Agency, PUB, indicated that the Aquaporin Inside® CLEAR biomimetic membrane achieved an impressive 20% energy savings.
- A pilot plant contract was secured in May to implement a Forward Osmosis system for Trinity College Dublin, advancing research aimed at recovering bio-based products.
- Aquaporin joined forces with Denmark's Water Alliance China and partners such as Grundfos to enhance industrial wastewater treatment in China.
- Continued fruitful partnerships with Gallo in the US have yielded excellent concentration outcomes at pilot scale.
Upcoming Events and Projections
Following the strategic review initiated in August, Aquaporin has recognized a need to bolster its financial standing. Plans are in motion to raise between DKK 125 million to DKK 175 million to realize growth ambitions as they approach profitability.
The Company's Board of Directors has decided to hold an extraordinary general meeting on December 1, 2025, to discuss proposals that will offer flexibility in structuring transactions aimed at capital raising, including equity financing opportunities.
As part of Mr. Jakobsen's commentary regarding the quarter, he highlighted a 14% revenue increase compared to the previous year, although total year-to-date revenue had decreased by 60%. Despite these figures, the company anticipates that a large part of the annual revenue will be recognized toward year's end, maintaining revenue expectations at DKK 40 to 50 million.
In summary, with DKK 8.8 million in cash and cash equivalents as of late September, Aquaporin continues to pursue strategies to augment its financial position and is eager to explore various avenues for capital investments.
Contact Information for Further Inquiries
For additional information, please reach out to:
Ulrik Lund Jakobsen, Chief Executive Officer
Klaus Juhl Wulff, Chief Financial Officer
+45 53 55 55 19
About Aquaporin
Aquaporin stands at the forefront of the water technology industry, operating across several regions including Denmark, Singapore, Turkey, the United States, and China. Our mission is to transform water filtration through biotechnology, addressing urgent global water challenges. We innovate by leveraging expertise in biology, chemistry, and physics to create the nature-inspired Aquaporin Inside® technology which is integral to our membranes and solutions.
Our technology, rooted in Nobel Prize-winning research, actively works to purify and reuse water in multiple settings—from industries to homes and even within NASA missions. We are proud to partner with global entities to responsibly manage industrial wastewater and enhance drinking water quality, as well as to enrich food and beverage product concentrations naturally.
Frequently Asked Questions
What is Aquaporin's core business focus?
Aquaporin specializes in innovative water technology, particularly rethinking water filtration using biotechnology and nature-inspired solutions.
How did Aquaporin's revenue perform in Q3 2025?
The company's revenue increased by 14% in Q3 2025, totaling DKK 4.1 million, compared to DKK 3.6 million in Q3 2024.
What are the company’s financial expectations for 2025?
Aquaporin has revised its revenue guidance for 2025 to DKK 40-50 million and expects an EBITDA loss between DKK (45) and (55) million.
What strategic actions is Aquaporin taking in response to its financial situation?
The company has initiated a strategic review aiming to raise capital between DKK 125 million and DKK 175 million to support future growth initiatives.
Where is Aquaporin headquartered?
Aquaporin is headquartered in Kongens Lyngby, Denmark, and extends its operations globally across several key locations.
